A Phase I, Randomised, Double Blind, Placebo Controlled, 3-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 May 2016
At a glance
- Drugs RPL 554 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Verona Pharma
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 18 May 2016 Results from healthy male population presented at the 112th International Conference of the American Thoracic Society
- 12 Aug 2015 Planned number of patients changed from 120 to 112 as reported by ClinicalTrials.gov record.